Cellectar Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference
September 20, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company (the “company”), today announced that president and CEO Jim...
Cellectar Biosciences Appoints Jarrod Longcor Chief Business Officer
September 18, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company (the “company”), announced that effective today Jarrod Longcor,...
Cellectar Biosciences to Present at the 19th Annual Rodman and Renshaw Global Investment Conference
September 06, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company (the “company”), today announced that it will present and meet...
Cellectar Biosciences Announces Significant PDC Platform Advancement; Demonstrates Potential to Improve Therapeutic Window
August 22, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces that its...
Cellectar Biosciences Reports Second Quarter 2017 Financial and Corporate Performance
August 14, 2017 16:45 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces financial...
Cellectar Biosciences’ CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced Multiple Myeloma Patients
August 08, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces its lead PDC...
Cellectar Biosciences to Host Conference Call on August 14, 2017 to Report Second Quarter 2017 Financial Results and Corporate Performance
August 03, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces that management...
Cellectar Biosciences Signs Collaboration with Avicenna Oncology to Develop New PDCs for Solid Tumors
August 01, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces the initiation of a...
Cellectar Biosciences to Present at the 2017 Marcum MicroCap Conference
June 06, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., June 06, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), an oncology-focused biotechnology company, today announced that president and CEO Jim Caruso will be presenting...
Cellectar Biosciences to Present at the LD Micro Invitational Conference
May 30, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., May 30, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), an oncology-focused biotechnology company, today announced that it will be presenting at the 7th annual LD Micro...